First Time in Human Study of Intravenous Interleukin-18 Antibody

PHASE1CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

January 5, 2010

Primary Completion Date

July 11, 2012

Study Completion Date

July 11, 2012

Conditions
Inflammatory Bowel Diseases
Interventions
DRUG

GSK1070806

"The study drug, GSK1070806, is a humanised monoclonal antibody. Antibodies are proteins that are made by white blood cells during an immune reaction. They circulate in the blood and attach to foreign proteins called antigens in order to destroy or neutralise them.~Humanised monoclonal antibodies are a type of protein that is genetically engineered to resemble a human protein (humanised). GSK1070806 is designed to block a specific protein that exists in the body called Interleukin-18. Interleukin-18 works within the immune system, i.e. the body's defence system, which helps protect it from disease, bacteria and viruses. Interleukin-18 activates the immune system to fight infections and may also occasionally cause inflammation."

Trial Locations (1)

CB2 2GG

GSK Investigational Site, Cambridge

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01035645 - First Time in Human Study of Intravenous Interleukin-18 Antibody | Biotech Hunter | Biotech Hunter